Brazil‘s National Health Surveillance Agency (Anvisa) granted this Wednesday authorization for clinical trials (phases 1 and 2) of the Butanvac vaccine, the immunizer developed by the Butantan Institute.

Before starting the vaccination of volunteers, Butantan should present some additional information about ongoing tests with the vaccine.

ButanVac’s clinical research will have three stages, with an expected participation of 6,000 volunteers. The authorization given today corresponds to phase A, in which around 400 people will participate.

The tests will be carried out by two teaching hospitals from the University of Sao Paulo (USP).

The Butantan Institute has already produced 7 million doses of the vaccine.